Can GLP-1s cause gallbladder problems?

Gallbladder events are among the better-documented GLP-1 risks: STEP trials reported cholelithiasis (gallstones) in ≈1.6% of semaglutide users versus ≈0.7% on placebo, with similar signals for tirzepatide. The honest mechanism story spreads the blame: - Rapid weight loss itself is a classic gallstone factory — losing >1.5 kg/week sharply raises risk regardless of method (it’s a known bariatric-surgery complication). Mobilized cholesterol concentrates in bile; sludge and stones follow. - The drugs may slow gallbladder emptying directly, adding stasis to the supersaturated bile. - Obesity itself predisposes to stones, so the baseline was elevated before anyone injected anything. The symptom signature (biliary colic): episodes of steady pain in the right upper abdomen or center, classically 30–60+ minutes after fatty meals, sometimes radiating to the right shoulder blade. Distinct from titration nausea by location and food-fat linkage. The urgent escalation: that pain plus fever, chills, vomiting, or yellowing of skin/eyes suggests cholecystitis or a blocked duct — same-day care, since blocked bile ducts also cause pancreatitis. Risk reduction that’s actually in your control: 1. Don’t race the loss — the ≈1%/week pace guideline again (why speed costs). 2. Don’t go ultra-low-fat. Counterintuitive but true: some dietary fat keeps the gallbladder contracting and flushing. Moderate fat regularly beats near-zero fat. 3. Known stones already? Tell your prescriber — usually not exclusionary if asymptomatic, but it changes the monitoring conversation. Active symptomatic gallbladder disease, by contrast, is a standard contraindication until treated. Perspective: gallbladder surgery (cholecystectomy), if it comes to that, is among the most routine operations in medicine — an inconvenience, not a catastrophe — but the better play is the pacing that avoids it.